News | April 29, 2025
Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Q2 FY25 Total Income was at Rs. 85.4 crore
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Vimta Labs has reported total income of Rs. 82.44 crores during the period ended June 30, 2024
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022
Subscribe To Our Newsletter & Stay Updated
